Ezesrol Tablets (Ezetimibe)

Adult dosage

The recommended dosage for this medication is 10 mg once daily, taken regardless of meals. When used in conjunction with HMG-CoA reductase inhibitors, it should be initiated at the recommended starting dose of the HMG-CoA reductase inhibitor along with this medication. If already receiving a high dose of an HMG-CoA reductase inhibitor, the dosage of the HMG-CoA reductase inhibitor should be maintained while combining it with this medication. In cases of combination with fenofibrate.

This medication should not be used in patients who are allergic to any of its components. Patients with active liver disease or abnormally high liver enzyme levels should not take this drug along with certain cholesterol-lowering agents. The use of this medication in combination with specific lipid-lowering agents is prohibited in pregnant or breastfeeding women, and women of childbearing potential should exercise special caution. Patients with severely impaired liver function, gallbladder disease, or severe renal dysfunction should avoid concomitant administration of this medication with certain lipid-lowering agents. Due to the inclusion of lactose, this medication is not to be administered to patients with lactose intolerance or related genetic disorders. Patients with moderate or severe liver impairment may experience increased exposure to this medication, leading to unexpected side effects, and thus it is not recommended. In clinical trials, this medication is generally well tolerated; however, side effects such as fatigue, abdominal pain, diarrhea, and myalgia may occur. Particularly when this medication is used in combination with other cholesterol-lowering agents, liver enzyme levels may rise, necessitating regular monitoring of liver function. If any unusual symptoms appear in the muscles, patients should notify their doctor immediately and discontinue use, as serious muscular disorders like myopathy or rhabdomyolysis may occur. Patients with impaired kidney function require more careful monitoring during treatment with this medication. There may be interactions with other medications, so patients should inform their doctor or pharmacist about any concomitant medications. There is no experience using this medication during pregnancy, so the potential risks and benefits of its use during pregnancy should be considered carefully. When breastfeeding, it is advisable not to use this medication unless absolutely necessary, as its effects on the infant are unknown. This medication is not recommended for children under 6 years of age, and it exhibits a safety profile similar to that of adults for children and adolescents over 6 years. It is generally safe for elderly patients, but some elderly individuals may display more sensitive reactions, requiring caution. In case of overdose, there is no specific treatment, and patients should seek appropriate care at a hospital immediately. This medication should be kept out of reach of children and should not be transferred to other containers.

Serious side effects

Urticaria, severe swelling (edema), anaphylaxis, hypersensitivity reactions including rashes and angioedema, hepatitis, thrombocytopenia, pancreatitis, skin-mucosal syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), difficulty breathing, jaundice of the skin or eyes, severe liver abnormalities, severe allergic reactions, severe skin reactions, severe neurological symptoms (headaches, confusion, visual disturbances, paralysis, etc.), severe edema

Mild side effects

• Fatigue
• abdominal pain
• diarrhea
• viral infections
• pharyngitis
• sinusitis
• arthralgia
• back pain
• cough
• chest pain

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It should be kept at room temperature between 1 degree and 30 degrees Celsius.

Appearance

White to almost white rectangular tablets

Package unit

30 tablets (10 tablets/PTP X 3)